Trinity Biotech Plc · NASDAQ:TRIB
Trinity Biotech — Q2 2025 Earnings Presentation
15 slides from Trinity Biotech's earnings presentation, Jun 30, 2025
Slide 1: Financial Results (Unaudited) For Quarter Ended June 30, 2025
Financial Results (Unaudited) For Quarter Ended June 30, 2025
Slide 2: Q2 2025 Financial Results - Summary
Q2 2025 Financial Results - Summary Overview • Revenue for the quarter ended as of 30 June 2025 was $10.8m vs $15.8m for the corresponding period in 2024. • As announced previously, Q2, 2025 remained a transitional quarter, impacted by temporary production reductions implemented to facilitate operat
Slide 3: Q2 2025 Revenue & Gross Profit
Q2 2025 Revenue & Gross Profit Revenue Overview • Total revenue: $10.8m, compared to $15.8m in Q2, 2024 • Like-for-like revenue (excluding sub-scale lower-margin third-party product lines): Q2, 2025: $10.7m vs Q2, 2024 $15.0m • Reduction in revenue compared to Q2, 2024 was driven primarily by; • Net
Slide 4: Q2 2025 Cost Base & Liquidity
Q2 2025 Cost Base & Liquidity • R&D expense: (Q2, 2025: $0.6m vs Q2 2024: $0.9m), with $1.7m capitalised, including $1.1m for CGM programme. • SG&A expense: (Q2, 2025: $7.0m vs Q2, 2024: $6.4m), with increase primarily driven both by foreign exchange loss resulting from the weakening of the US Dolla
Slide 5: Net Financing Expense
Net Financing Expense (US$’000’s) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Amended Term Loan interest 3,474 3,055 6,693 5,615 Convertible note interest 310 290 605 571 Notional interest on lease liabilities for Right-of-use assets 164 150 321 297 Fair value movement
Slide 6: EBITDA & Adjusted EBITDA Reconciliation
EBITDA & Adjusted EBITDA Reconciliation (US$’000’s) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Loss for the period on continuing operations (5,965) (6,757) (14,764) (10,074) Income tax expense/ (credit) 294 (131) 300 (64) Net financing expense 2,122 2,836 4,431 3,045 D
Slide 7: Use of Non-IFRS Financial Measures
Use of Non-IFRS Financial Measures The attached summary unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentatio
Slide 8: Forward-Looking Statements
Forward-Looking Statements This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resour
Slide 9: About Trinity Biotech
About Trinity Biotech Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a variety of health conditions including autoimmune, infectious and sexually transm
Slide 10: Consolidated Statement of Operations (unaudited)
Trinity Biotech PLC Consolidated Statement of Operations (unaudited) (US$000’s except share and per data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues 10,831 15,843 18,401 30,547 Cost of sales (6,218) (10,109) (11,880) (19,291) Gross profit 4,613 5,734 6,521 11,
Slide 11: Consolidated Balance Sheets
Trinity Biotech PLC Consolidated Balance Sheets (US$000’s) June 30, March 31, December 31, 2025 2025 2024 (unaudited) (unaudited) (audited) ASSETS Non-current assets Property, plant and equipment 4,309 4,382 4,621 Goodwill and intangible assets 55,919 53,656 51,343 Financial assets 2,763 2,553 2,455
Slide 12: Consolidated Balance Sheets - continued
Trinity Biotech PLC Consolidated Balance Sheets - continued (US$000’s) June 30, March 31, December 31, 2025 2025 2024 (unaudited) (unaudited) (audited) EQUITY AND LIABILITIES - continued Current liabilities Income tax payable 472 390 364 Trade and other payables 26,486 25,287 26,782 Exchangeable sen
Slide 13: Consolidated Statement of Cash Flows (unaudited)
Trinity Biotech PLC Consolidated Statement of Cash Flows (unaudited) (US$000’s) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Cash flows from operating activities Loss for the period (5,965) (6,757) (14,764) (10,074) Adjustments to reconcile loss to cash used in operating
Slide 14: Consolidated Statement of Cash Flows (unaudited)
Trinity Biotech PLC Consolidated Statement of Cash Flows (unaudited) (US$000’s) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Cash flows from financing activities Issue of ordinary share capital including share premium (net of issuance costs) - - 547 - Net proceeds from s
Slide 15: Investor Queries
Investor Queries Trinity Biotech Plc RedChip Companies Inc Paul Murphy David Gentry (353)-1-2769800 (1)-407-644-4256 [email protected] [email protected]